Peptide Based Metabolic Disorders Therapeutics Market Forecast Report

Posted by Arslan on February 25th, 2019

Ongoing research and development activities have maintained their focus on treatments for human ailments. The peptide therapeutics is used to treat various ailments, one such being the metabolic disorders. The global peptide based metabolic disorders therapeutics market is positively impacted by factors such as efficacy, safety, innovations in drug discovery, easy synchronization, stability, etc. Moreover, in addition to these factors, certain economic aspects also fuel the growth of the global peptide based metabolic disorders therapeutics market. The increasing investment in the healthcare industry and in research, the technological advancements, rise in biotech and pharmaceutical companies dealing with peptides. The increase in the metabolic disorder rate has made it imperative to develop new treatments with peptides and this has spurred the adoption of peptide therapeutics in the treatment of metabolic disorders, thereby contributing to the growth of the global peptide based metabolic disorders therapeutics market.

The global peptide based metabolic disorders therapeutics market is anticipated to show a value more than US$ 8 Bn and expected to grow at a robust rate during the period of forecast.

North America Domination in the Peptide Based Metabolic Disorders Therapeutics

With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of  revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share

APEJ Shows a Similar Growth Rate

The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.

Browse More Information about this Report @ https://www.factmr.com/report/187/peptide-based-metabolic-disorders-therapeutics-market

Liraglutide Dominates the Drug Class Category

The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.

Exenatide and Others Segments Have a Tie

The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.

Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth

The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.